0IRF Stock Overview
Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide.
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Evotec SE Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €9.81 |
| 52 Week High | €24.44 |
| 52 Week Low | €8.59 |
| Beta | 1.11 |
| 1 Month Change | -30.12% |
| 3 Month Change | -27.83% |
| 1 Year Change | -41.55% |
| 3 Year Change | -70.73% |
| 5 Year Change | -55.98% |
| Change since IPO | 684.97% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0IRF | GB Life Sciences | GB Market | |
|---|---|---|---|
| 7D | 5.1% | 7.4% | 1.0% |
| 1Y | -41.6% | -42.0% | 3.0% |
Return vs Industry: 0IRF matched the UK Life Sciences industry which returned -42% over the past year.
Return vs Market: 0IRF underperformed the UK Market which returned 3% over the past year.
Price Volatility
| 0IRF volatility | |
|---|---|
| 0IRF Average Weekly Movement | 10.9% |
| Life Sciences Industry Average Movement | 5.8% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 11.4% |
| 10% least volatile stocks in GB Market | 2.7% |
Stable Share Price: 0IRF's share price has been volatile over the past 3 months.
Volatility Over Time: 0IRF's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of UK stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1993 | 5,061 | Mario Polywka | www.evotec.com |
Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women’s health. It has collaboration agreements with SK bioscience, JingXin, Carrick Therapeutics, Sernova, Topas Therapeutics, Exscientia, CONBA Group, Centrexion, Sanofi/NIH, Kazia Therapeutics, Bristol Myers Squibb, Topas Therapeutics, Immunitas, Exscientia, and Bayer, as well as a strategic partnership with Dewpoint Therapeutics to advance its portfolio targeting biomolecular condensates as a novel domain for therapeutic intervention towards the clinic.
Evotec SE Fundamentals Summary
| 0IRF fundamental statistics | |
|---|---|
| Market cap | €1.73b |
| Earnings (TTM) | -€83.91m |
| Revenue (TTM) | €781.43m |
2.2x
P/S Ratio-20.6x
P/E RatioIs 0IRF overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0IRF income statement (TTM) | |
|---|---|
| Revenue | €781.43m |
| Cost of Revenue | €606.38m |
| Gross Profit | €175.05m |
| Other Expenses | €258.96m |
| Earnings | -€83.91m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 22, 2024
| Earnings per share (EPS) | -0.47 |
| Gross Margin | 22.40% |
| Net Profit Margin | -10.74% |
| Debt/Equity Ratio | 39.1% |
How did 0IRF perform over the long term?
See historical performance and comparison